Yuan Yuan et al., 2024-05: Earlier (SABCS 2023) design abstract for the same Cedars-Sinai trial, setting out the two-stage phase II stopping rule, the three ivermectin dose levels and the correlative aims; no outcome data.
In stage 1, a total of 13 PDL1-negative TNBC breast cancer patients will be treated at the RP2D. If there are no responders, the Phase 2 portion will close.
Yuan Yuan et al., 2024-05: Earlier (SABCS 2023) design abstract for the same Cedars-Sinai trial, setting out the two-stage phase II stopping rule, the three ivermectin dose levels and the correlative aims; no outcome data. C2. Study type: trial-design abstract, no patients reported. Planned accrual 34-41 (phase 1: 14-16; phase 2: 20-25). Dose: ivermectin 30/45/60 mg PO daily, days 1-3, 8-10, 15-17 of a 21-day cycle, plus balstilimab 450 mg IV; IQ 3+3 design. Pre-specified statistics: type I error 12% for a true response rate of 5%, power 88% for 20%. Funder and disclosures not printed in the abstract. Useful for the decision rule against which the 2025 results should be read. Study type: other.
